MX387203B - Pirrolopirimidinas como potenciadores de cftr. - Google Patents

Pirrolopirimidinas como potenciadores de cftr.

Info

Publication number
MX387203B
MX387203B MX2019005822A MX2019005822A MX387203B MX 387203 B MX387203 B MX 387203B MX 2019005822 A MX2019005822 A MX 2019005822A MX 2019005822 A MX2019005822 A MX 2019005822A MX 387203 B MX387203 B MX 387203B
Authority
MX
Mexico
Prior art keywords
sup
compounds
cftr
cystic fibrosis
pyrrolopyrimidines
Prior art date
Application number
MX2019005822A
Other languages
English (en)
Other versions
MX2019005822A (es
Inventor
Atli Thorarensen
Christoph Wolfgang Zapf
Daniel Elbaum
David Christopher Limburg
Ivan Viktorovich Efremov
John Paul Mathias
Joseph Walter Strohbach
Lori Krim Gavrin
Rajiah Aldrin Denny
Original Assignee
Cystic Fibrosis Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cystic Fibrosis Found filed Critical Cystic Fibrosis Found
Publication of MX2019005822A publication Critical patent/MX2019005822A/es
Publication of MX387203B publication Critical patent/MX387203B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula I, (ver Fórmula) en donde R1a, R1b, R2, R3, R4, W, Y y Z son como se describen en este documento, y a sales famacéuticamente aceptable de los mismos. Los compuestos son potenciadores del regulador de conductancia transmembranal de la fibrosis quística (CFTR). La invención también da a conocer composiciones farmacéuticas que comprenden el compuesto opcionalmente en combinación con agentes terapéuticos adicionales, y métodos de potenciación, en mamíferos incluyendo humanos, de CFTR por la administración de los compuestos. Estos compuestos son útiles para el tratamiento de fibrosis quística (CF), asma, bronquiectasia, enfermedad pulmonar obstructiva crónica (COPD), constipación, diabetes mellitus, xeroftalmia, pancreatitis, rinosinusitis, síndrome de Sjögren y otros trastornos asociados con CFTR.
MX2019005822A 2016-11-18 2017-11-17 Pirrolopirimidinas como potenciadores de cftr. MX387203B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423919P 2016-11-18 2016-11-18
PCT/US2017/062148 WO2018094137A1 (en) 2016-11-18 2017-11-17 Pyrrolopyrimidines as cftr potentiators

Publications (2)

Publication Number Publication Date
MX2019005822A MX2019005822A (es) 2019-09-09
MX387203B true MX387203B (es) 2025-03-18

Family

ID=62144793

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012639A MX2021012639A (es) 2016-11-18 2017-11-17 Pirrolopirimidinas como potenciadores de cftr.
MX2019005822A MX387203B (es) 2016-11-18 2017-11-17 Pirrolopirimidinas como potenciadores de cftr.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021012639A MX2021012639A (es) 2016-11-18 2017-11-17 Pirrolopirimidinas como potenciadores de cftr.

Country Status (22)

Country Link
US (5) US10301315B2 (es)
EP (2) EP4424311A3 (es)
JP (3) JP6978507B2 (es)
KR (2) KR102824092B1 (es)
CN (2) CN115850268B (es)
AU (2) AU2017362350B2 (es)
CA (1) CA3044050A1 (es)
CL (1) CL2019001334A1 (es)
CO (1) CO2019005993A2 (es)
CR (1) CR20190292A (es)
DO (1) DOP2019000126A (es)
EC (1) ECSP19043120A (es)
ES (1) ES2983686T3 (es)
IL (3) IL314404B1 (es)
MX (2) MX2021012639A (es)
PE (1) PE20200739A1 (es)
PH (1) PH12019501098A1 (es)
PL (1) PL3541390T3 (es)
RU (2) RU2757457C2 (es)
SG (1) SG10202106949XA (es)
UA (1) UA125400C2 (es)
WO (1) WO2018094137A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
IL313498A (en) 2014-10-06 2024-08-01 Vertex Pharma Modulators of the cystic fibrosis transmembrane conductance regulator
WO2017112853A1 (en) * 2015-12-22 2017-06-29 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
HRP20211683T1 (hr) 2016-09-30 2022-03-04 Vertex Pharmaceuticals Incorporated Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora
AU2017362350B2 (en) * 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
CN110300589B (zh) * 2016-12-16 2023-03-10 囊性纤维化基金会 作为cftr增效剂的双环异杂芳基衍生物
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP3980121A1 (en) * 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
MX2022000549A (es) 2019-07-15 2022-02-10 Novartis Ag Formulaciones de (s)-3-amino-6-metoxi-n-(3,3,3-trifluoro-2-hidroxi -2-metilpropil)-5-(trifluorometil)picolinamida.
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
EP4013760A1 (en) 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含ｃｆｔｒ調節劑化合物之點眼用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286892B6 (en) * 1992-12-17 2000-07-12 Pfizer Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
AU2002310187A1 (en) 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1730148A4 (en) * 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
TW201307354A (zh) * 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
EP2007767B1 (en) * 2006-03-11 2011-11-02 Vernalis (R&D) Ltd Pyrrolopyrimidine derivatives used as hsp90 inhibitors
AU2007347115A1 (en) * 2006-04-04 2008-10-23 The Regents Of The University Of California PI3 kinase antagonists
CN101917999A (zh) * 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
WO2013071232A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2015091532A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators

Also Published As

Publication number Publication date
SG10202106949XA (en) 2021-07-29
RU2019118623A3 (es) 2021-03-18
US20190225621A1 (en) 2019-07-25
RU2019118623A (ru) 2020-12-21
KR102824092B1 (ko) 2025-06-25
PE20200739A1 (es) 2020-07-24
CA3044050A1 (en) 2018-05-24
IL296279A (en) 2022-11-01
ECSP19043120A (es) 2019-08-30
IL266668A (en) 2019-07-31
MX2021012639A (es) 2022-10-03
AU2017362350A1 (en) 2019-06-20
JP6978507B2 (ja) 2021-12-08
KR20230146104A (ko) 2023-10-18
IL314404A (en) 2024-09-01
EP3541390A4 (en) 2020-06-24
IL266668B (en) 2022-10-01
IL314404B1 (en) 2025-09-01
EP4424311A2 (en) 2024-09-04
JP2022024023A (ja) 2022-02-08
PH12019501098A1 (en) 2019-09-09
CO2019005993A2 (es) 2019-07-31
US20200017512A1 (en) 2020-01-16
EP3541390B1 (en) 2024-05-01
CN110337294A (zh) 2019-10-15
NZ754085A (en) 2025-05-02
IL266668B2 (en) 2023-02-01
US10301315B2 (en) 2019-05-28
US20210171534A1 (en) 2021-06-10
JP7592814B2 (ja) 2024-12-02
AU2017362350B2 (en) 2021-12-23
AU2022201816A8 (en) 2022-04-21
ES2983686T3 (es) 2024-10-24
AU2022201816B2 (en) 2024-02-15
CR20190292A (es) 2019-09-03
BR112019010167A2 (pt) 2019-09-17
CN110337294B (zh) 2022-11-01
RU2021129721A (ru) 2021-11-26
MX2019005822A (es) 2019-09-09
UA125400C2 (uk) 2022-03-02
WO2018094137A1 (en) 2018-05-24
AU2022201816A1 (en) 2022-04-07
JP7360434B2 (ja) 2023-10-12
US20230250100A1 (en) 2023-08-10
RU2757457C2 (ru) 2021-10-18
EP3541390A1 (en) 2019-09-25
CN115850268B (zh) 2025-06-27
US10494374B2 (en) 2019-12-03
JP2023182694A (ja) 2023-12-26
KR102585398B1 (ko) 2023-10-10
US20180141954A1 (en) 2018-05-24
CN115850268A (zh) 2023-03-28
DOP2019000126A (es) 2019-08-30
EP4424311A3 (en) 2024-12-18
KR20190110088A (ko) 2019-09-27
PL3541390T3 (pl) 2024-09-09
JP2020510668A (ja) 2020-04-09
EP3541390C0 (en) 2024-05-01
CL2019001334A1 (es) 2019-11-15

Similar Documents

Publication Publication Date Title
MX387203B (es) Pirrolopirimidinas como potenciadores de cftr.
MX391651B (es) Derivados de heteroarilo biciclico como potenciadores de cftr.
BR112018007161A2 (pt) pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso
PH12018500088A1 (en) Substituted tricyclics and method of use
BR112018007145A2 (pt) ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
CU20120139A7 (es) Derivado de piridina y pirazina para el tratamiento de fibrosis quística(cf)
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
BR112018072047A2 (pt) moduladores da proteína reguladora de condutância transmembranar de fibrose cística
TW200630346A (en) Pyrimidines as prostaglandin D2 receptor antagonists
CL2008003494A1 (es) Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion.
JP2010504973A5 (es)
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
MX2014014710A (es) Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar).
JP2016540749A5 (es)
CO6640319A2 (es) Formulación en polvo seca que comprende una droga antimuscarínica
JP2018505192A5 (es)
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
MY196804A (en) Class of bifunctional compounds with quaternary ammonium salt structure
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
EA029678B9 (ru) Четвертичные соли пиперидиния
JP2014517034A5 (es)
EA201070056A1 (ru) N-оксид силденафила в качестве пролекарства
BR112017008790A2 (pt) cromanos substituídos e métodos de uso
CY1114902T1 (el) Ανταγωνιστες cgrp υποδοχεα